Panacea Index Logo

Command Palette

Search for a command to run...

Investigating the efficacy of acupuncture in treating patients with metabolic-associated fatty liver disease: a protocol for a randomised controlled clinical trial.

BMJ open
January 1, 1970
Lihong Fu et al. (11 authors)
Journal ArticleClinical Trial ProtocolResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine the efficacy of acupuncture versus sham acupuncture for treating metabolic-associated fatty liver disease (MAFLD).

Results Summary

The study protocol outlines a rigorous trial design to assess acupuncture's impact on liver fat reduction, metabolic markers, and gut microbiota, but results are not yet available as this is a protocol description.

Population

98 participants with MAFLD.

Effective Dosage

Not specified (frequency/duration: 12 weeks).

Duration

12 weeks of intervention, with follow-up at 24 weeks.

Interactions

None mentioned.

Extracted Claims (15)
InterventionDirectionEndpointPopulationDosageImpactClaim #
acupuncture
neutral
metabolic-associated fatty liver disease (MAFLD) treatment
participants with MAFLD
-
determine the efficacy
#1
acupuncture versus sham acupuncture (SHA)
neutral
MAFLD treatment
participants with MAFLD
-
determine the efficacy
#2
acupuncture or SHA
decrease
liver fat after 12 weeks of treatment in MRI-proton density fat fraction (MRI-PDFF)
participants with MAFLD
30% relative decline
primary outcome is the rate of patients with a 30% relative decline
#3
acupuncture or SHA
neutral
relative liver fat content measured by MRI-PDFF
participants with MAFLD
-
secondary outcomes include the changes
#4
acupuncture or SHA
neutral
magnetic resonance elastography
participants with MAFLD
-
secondary outcomes include the changes
#5
acupuncture or SHA
neutral
liver function
participants with MAFLD
-
secondary outcomes include the changes
#6
acupuncture or SHA
neutral
lipid metabolism
participants with MAFLD
-
secondary outcomes include the changes
#7
acupuncture or SHA
neutral
homeostatic model assessment for insulin resistance (HOMA-IR)
participants with MAFLD
-
secondary outcomes include the changes
#8
acupuncture or SHA
neutral
serum high sensitivity C reactive protein
participants with MAFLD
-
secondary outcomes include the changes
#9
acupuncture or SHA
neutral
body mass index
participants with MAFLD
-
body measurement indicators
#10
acupuncture or SHA
neutral
waist circumference
participants with MAFLD
-
body measurement indicators
#11
acupuncture or SHA
neutral
hip circumference
participants with MAFLD
-
body measurement indicators
#12
acupuncture or SHA
neutral
waist-to-hip ratio
participants with MAFLD
-
body measurement indicators
#13
acupuncture or SHA
neutral
gut microbiota composition
participants with MAFLD
-
alteration
#14
acupuncture or SHA
neutral
gut microbiota metabolism
participants with MAFLD
-
alteration
#15
Abstract

INTRODUCTION: Acupuncture is widely used for metabolic-associated fatty liver disease (MAFLD) treatment; however, the clinical efficacy has not been confirmed due to the lack of high-level evidence-based clinical practice. The purpose of this study is to design a research protocol that will be used to determine the efficacy of acupuncture versus sham acupuncture (SHA) for MAFLD treatment. METHODS AND ANALYSIS: This will be a multicentre, randomised and sham-controlled trial. Ninety-eight participants with MAFLD will be enrolled in this trial. Participants will be randomly assigned in a 1:1 ratio to receive acupuncture or SHA for 12 weeks. The primary outcome is the rate of patients with a 30% relative decline in liver fat after 12 weeks of treatment in MRI-proton density fat fraction (MRI-PDFF), which will be obtained by quantitative chemical shift imaging such as the multipoint Dixon method at 0, 12 and 24 weeks. Secondary outcomes include the changes in the relative liver fat content measured by MRI-PDFF, magnetic resonance elastography, liver function, lipid metabolism, homeostatic model assessment for insulin resistance (HOMA-IR) and serum high sensitivity C reactive protein, which will be obtained at 0, 6, 12 and 24 weeks. Body measurement indicators (body mass index, waist circumference, hip circumference and waist-to-hip ratio) will be obtained at 0, 3, 6, 9, 12 and 24 weeks. The alteration in the gut microbiota composition and its metabolism will be assessed by 16S ribosomal RNA sequencing and liquid chromatography-mass spectrometry at 0 and 12 weeks. ETHICS AND DISSEMINATION: This study protocol has been approved by the ethics committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (2023-1347-114-01). The results of this study will be published in a peer-reviewed journal and presented at academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2300075701.

Medical Subject Headings (MeSH)
HumansAcupuncture TherapyNon-alcoholic Fatty Liver DiseaseRandomized Controlled Trials as TopicMagnetic Resonance ImagingTreatment OutcomeAdultMulticenter Studies as TopicMiddle AgedMaleFemaleInsulin ResistanceLiver
Study Links
Quality Scores
SafetyNot Assessed
Efficacy50/10
Quality80/10
Citation Metrics
Total Citations3
Citations/Year3.0
Research Impact Scores
APT Score0.25
Weight Score1.52
Normalized Score0.56
Related Supplements